Literature DB >> 8082506

CCK-receptor antagonists proglumide and loxiglumide stimulate bile flow and biliary glutathione excretion.

K Sztefko1, P Li, N Ballatori, W Y Chey.   

Abstract

The mechanism for the choleresis induced by CCK-receptor antagonists, proglumide, loxiglumide, and CR 1409, was examined in anesthetized rats and compared to the effects of CCK itself. These agents were infused intravenously over a 2-hr period, and bile flow, and biliary excretion of bicarbonate, total bile acids, and glutathione were measured in 30-min intervals. All three antagonists produced a dose-dependent choleresis, but a significant decrease in bile acid excretion, indicating that they stimulate bile flow via a bile acid-independent mechanism. The increase in bile flow was associated with a parallel increase in biliary glutathione and bicarbonate output in rats treated with proglumide and loxiglumide. In animals pretreated with acivicin to inhibit gamma-glutamyltransferase activity, proglumide was shown to stimulate biliary excretion of reduced glutathione (GSH), but not glutathione disulfide (GSSG), indicating the absence of oxidative stress in the liver. GSH output was increased by only 0.5-0.9 mumol/30 min after infusion of proglumide at a dose of 75 mg/kg/hr, whereas bile volume was increased 0.2-0.4 ml/30 min, indicating that this increased biliary GSH excretion can account for only a small fraction of the increased bile volume, given an osmotic efficiency for GSH of 34 microliters/mumol. In contrast to CCK receptor antagonists, CCK itself had no effect on bile flow and outputs of bicarbonate, GSH, and bile acids, suggesting that the effects of the antagonists are not related to their interaction with CCK receptors. These findings demonstrate that proglumide and loxiglumide stimulate a bile acid-independent bile flow that is only partially explained by an increase in GSH excretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082506     DOI: 10.1007/bf02088134

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  [Effect of proglumide on choleresis in rats].

Authors:  J Zhang; Y Liu; Q Z Xu
Journal:  Zhongguo Yao Li Xue Bao       Date:  1989-03

2.  Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.

Authors:  M Niederau; C Niederau; G Strohmeyer; J H Grendell
Journal:  Am J Physiol       Date:  1989-01

3.  New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.

Authors:  F Makovec; R Chistè; M Bani; M A Pacini; I Setnikar; L A Rovati
Journal:  Arzneimittelforschung       Date:  1985

4.  The effect of cholecystokinin-receptor antagonists on cholecystokinin-stimulated bile flow in dogs.

Authors:  S Westfall; C Andrus; D Schlarman; D L Kaminski
Journal:  Surgery       Date:  1991-03       Impact factor: 3.982

5.  Proglumide analogues: potent cholecystokinin receptor antagonists.

Authors:  R T Jensen; R B Murphy; M Trampota; L H Schneider; S W Jones; J M Howard; J D Gardner
Journal:  Am J Physiol       Date:  1985-08

6.  The cholecystokinin receptor antagonist CR1409 increases plasma cholecystokinin in rats.

Authors:  J B Jansen; A J de Jong; C B Lamers
Journal:  Regul Pept       Date:  1989-02

7.  Inhibitory effect of CR-1409, a competitive inhibitor of cholecystokinin, on pancreatic exocrine secretion in the conscious rat.

Authors:  K Miyasaka; R Nakamura; A Funakoshi; K Kitani
Journal:  Tohoku J Exp Med       Date:  1988-06       Impact factor: 1.848

8.  [Effects of cholecystokinin, gastrin and proglumide on bile secretion in rats].

Authors:  J Zhang; Y Liu; Q Z Xu
Journal:  Sheng Li Xue Bao       Date:  1990-04

9.  Intrabiliary glutathione hydrolysis. A source of glutamate in bile.

Authors:  N Ballatori; R Jacob; J L Boyer
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

10.  Structural features of various proglumide-related cholecystokinin receptor antagonists.

Authors:  R T Jensen; Z C Zhou; R B Murphy; S W Jones; I Setnikar; L A Rovati; J D Gardner
Journal:  Am J Physiol       Date:  1986-12
View more
  3 in total

1.  A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.

Authors:  Robin D Tucker; Victor Ciofoaia; Sandeep Nadella; Martha D Gay; Hong Cao; Matthew Huber; Anita Safronenka; Narayan Shivapurkar; Bhaskar Kallakury; Annie J Kruger; Alexander H K Kroemer; Jill P Smith
Journal:  Dig Dis Sci       Date:  2019-07-11       Impact factor: 3.199

2.  Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.

Authors:  Martha D Gay; Hong Cao; Narayan Shivapurkar; Sivanesan Dakshanamurthy; Bhaskar Kallakury; Robin D Tucker; John Kwagyan; Jill P Smith
Journal:  Int J Mol Sci       Date:  2022-02-08       Impact factor: 6.208

3.  Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment.

Authors:  Christine C Hsu; Sunil Bansal; Hong Cao; Coleman I Smith; Aiwu Ruth He; Martha D Gay; Yaoxiang Li; Amrita Cheema; Jill P Smith
Journal:  Pharmaceutics       Date:  2022-03-12       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.